Suppr超能文献

针对癌症中 ABCB1 启动子易位的靶向纳米孔测序。

Targeted nanopore sequencing for the identification of ABCB1 promoter translocations in cancer.

机构信息

Leukaemia Biology Laboratory, Cancer Research UK Manchester Institute, Oglesby Cancer Research Building, The University of Manchester, Manchester, M20 4GJ, UK.

Molecular Biology Core Facility, Cancer Research UK Manchester Institute, The University of Manchester, Alderley Park, Cheshire, SK10 4TG, UK.

出版信息

BMC Cancer. 2020 Nov 10;20(1):1075. doi: 10.1186/s12885-020-07571-0.

Abstract

BACKGROUND

Resistance to chemotherapy is the most common cause of treatment failure in acute myeloid leukemia (AML) and the drug efflux pump ABCB1 is a critical mediator. Recent studies have identified promoter translocations as common drivers of high ABCB1 expression in recurrent, chemotherapy-treated high-grade serous ovarian cancer (HGSC) and breast cancer. These fusions place ABCB1 under the control of a strong promoter while leaving its open reading frame intact. The mechanisms controlling high ABCB1 expression in AML are largely unknown. We therefore established an experimental system and analysis pipeline to determine whether promoter translocations account for high ABCB1 expression in cases of relapsed human AML.

METHODS

The human AML cell line THP-1 was used to create a model of chemotherapy resistance in which ABCB1 expression was driven by a promoter fusion. The THP-1 model was used to establish a targeted nanopore long-read sequencing approach that was then applied to cases of ABCB1 HGSC and AML. H3K27Ac ChIP sequencing was used to assess the activity of native promoters in cases of ABCB1 AML.

RESULTS

Prolonged in vitro daunorubicin exposure induced activating ABCB1 promoter translocations in human THP-1 AML cells, similar to those recently described in recurrent high-grade serous ovarian and breast cancers. Targeted nanopore sequencing proved an efficient method for identifying ABCB1 structural variants in THP-1 AML cells and HGSC; the promoter translocations identified in HGSC were both previously described and novel. In contrast, activating ABCB1 promoter translocations were not identified in ABCB1 AML; instead H3K27Ac ChIP sequencing demonstrated active native promoters in all cases studied.

CONCLUSIONS

Despite frequent high level expression of ABCB1 in relapsed primary AML we found no evidence of ABCB1 translocations and instead confirmed high-level activity of native ABCB1 promoters, consistent with endogenous regulation.

摘要

背景

化疗耐药是急性髓细胞白血病(AML)治疗失败的最常见原因,而 ABCB1 药物外排泵是一个关键的介导者。最近的研究已经确定启动子易位是复发性、化疗治疗的高级别浆液性卵巢癌(HGSC)和乳腺癌中 ABCB1 高表达的常见驱动因素。这些融合将 ABCB1 置于一个强大的启动子的控制之下,同时保持其开放阅读框的完整。AML 中控制 ABCB1 高表达的机制在很大程度上尚不清楚。因此,我们建立了一个实验系统和分析管道,以确定启动子易位是否导致复发性人类 AML 中 ABCB1 高表达。

方法

使用人 AML 细胞系 THP-1 建立了一个化疗耐药模型,其中 ABCB1 表达由启动子融合驱动。THP-1 模型用于建立靶向纳米孔长读测序方法,然后应用于 ABCB1 HGSC 和 AML 病例。H3K27Ac ChIP 测序用于评估 ABCB1 AML 病例中天然启动子的活性。

结果

体外延长柔红霉素暴露诱导人 THP-1 AML 细胞中激活的 ABCB1 启动子易位,类似于最近在复发性高级别浆液性卵巢癌和乳腺癌中描述的那些易位。靶向纳米孔测序被证明是一种有效的方法,用于鉴定 THP-1 AML 细胞和 HGSC 中的 ABCB1 结构变异;在 HGSC 中鉴定的启动子易位既有先前描述的,也有新的。相比之下,在 ABCB1 AML 中没有发现激活的 ABCB1 启动子易位;相反,H3K27Ac ChIP 测序显示所有研究病例中均有高活性的天然 ABCB1 启动子。

结论

尽管复发的原发性 AML 中经常出现高水平的 ABCB1 表达,但我们没有发现 ABCB1 易位的证据,而是证实了天然 ABCB1 启动子的高水平活性,这与内源性调节一致。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验